Cargando…

Embolia Cutis Medicamentosa after Subcutaneous Injection with Glatiramer Acetate

Embolia cutis medicamentosa (ECM) is a rare and unpredictable injection site reaction, occurring after intramuscular, subcutaneous, and even after intraarticular injection of various drugs. We report a very rare case of necrotizing ECM after injection of glatiramer acetate for multiple sclerosis, in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vlahova, Lyubomira, Kretschmer, Lutz, Schön, Michael P., Mössner, Rotraut
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	S. Karger AG 2021
Materias:	Single Case
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7989669/ https://www.ncbi.nlm.nih.gov/pubmed/33790754 http://dx.doi.org/10.1159/000510017

Ejemplares similares

Embolia cutis medicamentosa: an unusual adverse reaction to terlipressin
por: Gatos-Gatopoulos, Polychronis, et al.
Publicado: (2017)

Embolia cutis Medicamentosa (Nicolau syndrome): case series
por: Fekete, Gyula Laszlo, et al.
Publicado: (2023)

Recurrent Nicolau syndrome associated with subcutaneous glatiramer acetate injection—a case report
por: Zecca, Chiara, et al.
Publicado: (2015)

Nicolau syndrome following subcutaneous glatiramer acetate injection: A case report and review of the literature
por: Esme, Pelin, et al.
Publicado: (2021)

Two decades of subcutaneous glatiramer acetate injection: current role of the standard dose, and new high-dose low-frequency glatiramer acetate in relapsing–remitting multiple sclerosis treatment
por: Caporro, Matteo, et al.
Publicado: (2014)

Bullous pemphigoid as an injection site reaction of glatiramer acetate
por: Baghbanian, Seyed Mohammad, et al.
Publicado: (2019)

Interacciones medicamentosas
Publicado: (2009)

Follow-on glatiramer acetate
por: Cohen, Jeffrey A., et al.
Publicado: (2018)

Intralesional Avirulent Bacillus Calmette-Guérin Injection as a Promising Method for the Treatment of Tuberculosis Verrucosa Cutis
por: Gündüz, Özgür, et al.
Publicado: (2022)

"Interacciones Medicamentosas" : Revisión Bibliográfica /
por: Vello Sánchez, Godofredo
Publicado: (1987)

Aplasia Cutis Congenita: A Case Report
por: Magliah, Tahani, et al.
Publicado: (2018)

Embolia : revisión bibliográfica /
por: Ocampo Ayala, Josefina
Publicado: (1988)

Unilateral Idiopathic Calcinosis Cutis: A Case Report
por: Alsaif, Fahad, et al.
Publicado: (2017)

Tolerability and safety of novel half milliliter formulation of glatiramer acetate for subcutaneous injection: an open-label, multicenter, randomized comparative study
por: Anderson, G., et al.
Publicado: (2010)

Reacciones adversas medicamentosas : valoración clínica
por: Pelta Fernández, Roberto
Publicado: (1992)

Glatiramer acetate in the treatment of multiple sclerosis
por: Tselis, Alex, et al.
Publicado: (2007)

Interacciones medicamentosas de bolsillo
por: Lépori, Luis Raúl
Publicado: (2002)

Manual de prescripción medicamentosa
por: Rivas Vilchis, José F.
Publicado: (1983)

A Patient Care Program for Adjusting the Autoinjector Needle Depth According to Subcutaneous Tissue Thickness in Patients With Multiple Sclerosis Receiving Subcutaneous Injections of Glatiramer Acetate
por: Masid, Maria Luisa Sánchez, et al.
Publicado: (2015)

A Case of Aplasia Cutis Congenita Type VI: Bart Syndrome
por: Alfayez, Yasmin, et al.
Publicado: (2017)

Demonstration of Equivalence of Generic Glatiramer Acetate and Copaxone(®)
por: Lipsky, Peter, et al.
Publicado: (2021)

Embolia de líquido amniótico
por: Tapia Morales, Galación
Publicado: (1996)

Embolia por líquido amniótico /
por: Cruz Soto, Amalia
Publicado: (1988)

Tratamiento médico antirrítmico de la fibrilación auricular y flutter, de diferentes etiologías, con o sin presencia de embolias, por la sinergia medicamentosa de quinidina y verapamil
Publicado: (1992)

The role of glatiramer acetate in the early treatment of multiple sclerosis
por: Brandes, David W
Publicado: (2010)

Spasticity in multiple sclerosis and role of glatiramer acetate treatment
por: Meca-Lallana, Jose Eustasio, et al.
Publicado: (2015)

Glatiramer Acetate-associated Refractory Immune Thrombocytopenic Purpura
por: Sagy, Iftach, et al.
Publicado: (2016)

Physicochemical and Biological Examination of Two Glatiramer Acetate Products
por: Komlosh, Arthur, et al.
Publicado: (2019)

Glatiramer Acetate Immunomodulation: Evidence of Neuroprotection and Cognitive Preservation
por: Kasindi, Arielle, et al.
Publicado: (2022)

An Immunomodulatory Peptide Dendrimer Inspired from Glatiramer Acetate
por: Erzina, Dina, et al.
Publicado: (2021)

Bases farmacológicas de la terapéutica medicamentosa /
Publicado: (1969)

Escitalopram-Induced Skin Rash: Dermatitis Medicamentosa
por: Godi, Sangha M, et al.
Publicado: (2022)

Nicolau Syndrome After Glatiramer Acetate Injection in Close Proximity to Administration of SARS-CoV-2 mRNA Vaccine
por: Sy, Michael Yu, et al.
Publicado: (2021)

Síndrome de embolia grasa : revisión bibliográfica /
por: Guerrero Alarcón, Jorge
Publicado: (1987)

Molecular Profiling of Glatiramer Acetate Early Treatment Effects in Multiple Sclerosis
por: Achiron, Anat, et al.
Publicado: (2009)

Adherence to glatiramer acetate treatment for multiple sclerosis: the Brazilian experience
por: de Oliveira, Tatiana de Melo Gomes, et al.
Publicado: (2008)

Glatiramer acetate desensitisation in multiple sclerosis patients - the case report
por: Novotna, Bronislava, et al.
Publicado: (2014)

Effectiveness of glatiramer acetate compared to other multiple sclerosis therapies
por: Izquierdo, Guillermo, et al.
Publicado: (2015)

Neuroprotection with glatiramer acetate: evidence from the PreCISe trial
por: Arnold, Douglas L., et al.
Publicado: (2013)

Metabolic response to glatiramer acetate therapy in multiple sclerosis patients
por: De Riccardis, Lidia, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_2ohacdffr77m3g75k7hrcfpp7b